



Company Announcement no. 6/2016

To: NASDAQ Copenhagen A/S

Hørsholm, Denmark, 6 April, 2016

Veloxis announces change in management

Veloxis Pharmaceuticals A/S (NASDAQ: VELO) announced today that Johnny Stilou will step down as EVP & Chief Financial Officer as part of the Company's decision to close down all Danish activities and move to the US.

Johnny Stilou will remain with the Company until the end of August 2016 to secure the transition of activities to the US.

"Johnny has been with the Company for eight years and I would like to thank him for his very significant contributions to the development and transformation of Veloxis from a development stage company to commercialization in the EU and US" said Craig Collard, President & CEO.

For more information, please contact:

Veloxis Pharmaceuticals A/S
Craig A. Collard
President & CEO
Phone: +1 919 524 4317
Email: cac@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis' unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ Copenhagen under the trading symbol NASDAQ: VELO.

For further information, please visit www.veloxis.com.